Rystiggo®▼ USA In the U.S. RYSTIGGO® (rozanolixizumab-noli) is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. Europe In Europe, RYSTIGGO® (rozanolixizumab) is indicated as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. Prescribing information USA RYSTIGGO® prescribing information USA - June 2024 Prescribing information Europe RYSTIGGO® SmPC (Sourced from www.ema.europa.eu) ▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
